美国 · SEC FORM 4
Savara Inc
SVRA · Nasdaq · CIK 0001160308 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
15 同一窗口内观察到的 Form 4 交易行
1 sales · 14 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-06-20 · Hawkins Richard J.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 43,563,969
- 上期报告
- 43,343,616
- 日均成交量
- 2,526,580
- 回补天数
- 17.2
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-06-20 | Hawkins Richard J | 买入 (P) | Common Stock | 48,225 | USD 2.04 | USD 98,379 | SEC 申报 ↗ |
| 2025-05-29 | McCracken Joseph S | 买入 (P) | Common Stock | 10,000 | USD 2.08 | USD 20,800 | SEC 申报 ↗ |
| 2025-03-31 | RAMSAY DAVID A | 买入 (P) | Common Stock | 150,000 | USD 2.78 | USD 417,000 | SEC 申报 ↗ |
| 2024-11-19 | McCracken Joseph S | 买入 (P) | Common Stock | 20,000 | USD 2.95 | USD 59,000 | SEC 申报 ↗ |
| 2024-11-18 | RAMSAY DAVID A | 买入 (P) | Common Stock | 100,000 | USD 2.88 | USD 288,000 | SEC 申报 ↗ |
| 2023-07-17 | Yang Rick | 买入 (P) | Common Stock | 333,333 | USD 3.00 | USD 999,999 | SEC 申报 ↗ |
| 2023-07-17 | Walker Paul Edward | 买入 (P) | Common Stock | 333,333 | USD 3.00 | USD 999,999 | SEC 申报 ↗ |
| 2023-07-17 | SANDELL SCOTT D | 买入 (P) | Common Stock | 333,333 | USD 3.00 | USD 999,999 | SEC 申报 ↗ |
| 2023-07-17 | Mathers Edward T | 买入 (P) | Common Stock | 333,333 | USD 3.00 | USD 999,999 | SEC 申报 ↗ |
| 2023-07-17 | Makhzoumi Mohamad | 买入 (P) | Common Stock | 333,333 | USD 3.00 | USD 999,999 | SEC 申报 ↗ |
| 2023-07-17 | Growth Equity Opportunities 17, LLC; NEA 17 GP, LLC; NEA Partners 17, L.P.; New Enterprise Associates 17, L.P. | 买入 (P) | Common Stock | 333,333 | USD 3.00 | USD 999,999 | SEC 申报 ↗ |
| 2023-07-17 | Florence Anthony A. Jr. | 买入 (P) | Common Stock | 333,333 | USD 3.00 | USD 999,999 | SEC 申报 ↗ |
| 2023-07-17 | Chang Carmen | 买入 (P) | Common Stock | 333,333 | USD 3.00 | USD 999,999 | SEC 申报 ↗ |
| 2023-07-17 | Behbahani Ali | 买入 (P) | Common Stock | 333,333 | USD 3.00 | USD 999,999 | SEC 申报 ↗ |
| 2023-07-17 | BASKETT FOREST | 买入 (P) | Common Stock | 333,333 | USD 3.00 | USD 999,999 | SEC 申报 ↗ |
Form 4 申报证据
47 transaction lines in the latest 365-day window; 197 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | Parker Braden C. | 代扣税 (F) | Common Stock | 29,323 | USD 5.07 | USD 148,668 | SEC 申报 ↗ |
| 2026-07-15 | Lutz Robert Matthew | 奖励／授予 (A) | Common Stock | 35,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-22 | Lowrance David L | 卖出 (S) | Common Stock | 394,528 | USD 5.68 | USD 2,240,919 | SEC 申报 ↗ |
展开近期 Form 4 证据 (27 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | Parker Braden C. | 代扣税 (F) | Common Stock | 29,323 | USD 5.07 | USD 148,668 | SEC 申报 ↗ |
| 2026-07-15 | Lutz Robert Matthew | 奖励／授予 (A) | Common Stock | 35,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-22 | Lowrance David L | 卖出 (S) | Common Stock | 394,528 | USD 5.68 | USD 2,240,919 | SEC 申报 ↗ |
| 2026-06-22 | Lowrance David L | 期权行权／转换 (M) | Common Stock | 580,187 | USD 1.76 | USD 1,021,116 | SEC 申报 ↗ |
| 2026-06-22 | Lowrance David L | 代扣税 (F) | Common Stock | 185,659 | USD 5.50 | USD 1,021,124 | SEC 申报 ↗ |
| 2026-03-18 | Lowrance David L | 期权行权／转换 (M) | Common Stock | 366,747 | USD 1.60 | USD 588,455 | SEC 申报 ↗ |
| 2026-03-18 | Lowrance David L | 代扣税 (F) | Common Stock | 116,760 | USD 5.04 | USD 588,470 | SEC 申报 ↗ |
| 2026-02-16 | McCracken Joseph S | 期权行权／转换 (M) | Common Stock | 1,807 | USD 1.76 | USD 3,180 | SEC 申报 ↗ |
| 2025-12-19 | RAMSAY DAVID A | 卖出 (S) | Common Stock | 20,000 | USD 6.06 | USD 121,200 | SEC 申报 ↗ |
| 2025-12-16 | Pauls Matthew | 赠与 (G) | Common Stock | 128,995 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-16 | Lowrance David L | 赠与 (G) | Common Stock | 32,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-14 | Pauls Matthew | 代扣税 (F) | Common Stock | 195,705 | USD 6.92 | USD 1,354,279 | SEC 申报 ↗ |
| 2025-12-14 | McCabe Kathleen R. | 代扣税 (F) | Common Stock | 39,350 | USD 6.92 | USD 272,302 | SEC 申报 ↗ |
| 2025-12-14 | Lutz Robert Matthew | 代扣税 (F) | Common Stock | 67,760 | USD 6.92 | USD 468,899 | SEC 申报 ↗ |
| 2025-12-14 | Lowrance David L | 代扣税 (F) | Common Stock | 62,960 | USD 6.92 | USD 435,683 | SEC 申报 ↗ |
| 2025-12-14 | Erickson Anne | 代扣税 (F) | Common Stock | 62,960 | USD 6.92 | USD 435,683 | SEC 申报 ↗ |
| 2025-12-10 | Pauls Matthew | 赠与 (G) | Common Stock | 23,629 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | van Es-Johansson An | 奖励／授予 (A) | Common Stock | 40,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | RAMSAY DAVID A | 奖励／授予 (A) | Common Stock | 40,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | McCracken Joseph S | 奖励／授予 (A) | Common Stock | 40,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | Hawkins Richard J | 奖励／授予 (A) | Common Stock | 40,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | Elam Nevan C | 奖励／授予 (A) | Common Stock | 40,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-04 | Wasfi Yasmine | 代扣税 (F) | Common Stock | 21,992 | USD 6.37 | USD 140,089 | SEC 申报 ↗ |
| 2025-12-02 | Elam Nevan C | 期权行权／转换 (M) | Common Stock | 5,860 | USD 1.46 | USD 8,556 | SEC 申报 ↗ |
| 2025-12-02 | Elam Nevan C | 代扣税 (F) | Common Stock | 1,473 | USD 5.81 | USD 8,558 | SEC 申报 ↗ |
| 2025-11-14 | Hawkins Richard J | 期权行权／转换 (M) | Common Stock | 5,860 | USD 1.46 | USD 8,556 | SEC 申报 ↗ |
| 2025-10-20 | Wasfi Yasmine | 奖励／授予 (A) | Common Stock | 35,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SVRA |
| CIK | 0001160308 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 197 transaction lines from 2020-09-15 to 2026-09-24 87 P purchase lines · 9 S sale lines · 101 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.